Ypsomed's core delivery systems business delivered 17.5% sales growth in the first half of fiscal 2026/27, driven by auto-injector sales, which supported a favorable product mix and EBIT margin of nearly 36% despite ongoing capacity expansion. Shares rose 5% in trading on Nov. 11.
Ypsomed benefits from several secular growth drivers, including rising biologics development requiring injectables, expanding biosimilars, and surging GLP-1 drug demand.
Ypsomed and SHL Medical's focus on large-volume drugs could leave smaller biotech companies underserved, creating an opening for smaller competitors to gain traction.
Metric | YPSN | STVN | ATR |
|---|---|---|---|
Price/Earnings (Normalized) | 31.30 | 21.73 | 26.30 |
Price/Book Value | 6.85 | 2.04 | 3.49 |
Price/Sales | 8.06 | 2.55 | 2.34 |
Price/Cash Flow | 22.61 | 12.16 | 13.15 |
Metric | YPSN | STVN | ATR |
|---|---|---|---|
Quick Ratio | 0.69 | 1.18 | 0.90 |
Current Ratio | 0.94 | 1.73 | 1.50 |
Interest Coverage | 74.56 | 38.12 | 6.29 |
Metric | YPSN | STVN | ATR |
|---|---|---|---|
Return on Assets (Normalized) | 12.49% | 1.95% | 6.77% |
Return on Equity (Normalized) | 21.49% | 3.28% | 13.07% |
Return on Invested Capital (Normalized) | 16.71% | 2.67% | 9.42% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Intuitive Surgical Inc ISRG | LOCK|%%^#@jn | LOCK|Fs | $156B | |||
| Becton Dickinson & Co BDX | LOCK|y# | LOCK|<^mp | $58B | |||
| Alcon Inc ALC | LOCK|mQ!m<z | LOCK|fM%N | $36B | |||
| Medline Inc Ordinary Shares - Class A MDLN | LOCK|p&qqWsD | LOCK|h#M@r | $36B | |||
| ResMed Inc RMD | LOCK|h#@B<>! | LOCK|D!GY! | $33B | |||
| West Pharmaceutical Services Inc WST | LOCK|hYbt$RQ | LOCK|Tx> | $29B | |||
| Solventum Corp SOLV | LOCK|jnjP$M | LOCK|Sr | $15B | |||
| Baxter International Inc BAX | LOCK|@F | LOCK|%%!< | $14B | |||
| Align Technology Inc ALGN | LOCK|xc@P$VK | LOCK|$mpfv | $12B | |||
| The Cooper Companies Inc COO | LOCK|C<@D$w | LOCK|&#H> | $12B |
United States